Dianthus EVP exercises options, sells 114,367 shares
Dianthus Therapeutics EVP, CFO & CBO Ryan Savitz exercised stock options and sold the resulting shares.
Rhea-AI Filing Summary
Dianthus Therapeutics EVP, CFO & CBO Ryan Savitz exercised stock options and sold the resulting shares. On March 31, 2026, he exercised options to acquire 114,367 shares of common stock, including 74,367 shares at an exercise price of $8.44 and 40,000 shares at $17.88 per share. He then sold 114,367 shares of common stock in a series of open-market transactions at weighted average prices ranging from about $78.33 to $85.54 per share, under a Rule 10b5-1 trading plan adopted on December 30, 2025. Following these transactions, the filing shows he directly owns no shares of common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 114,367 shares ($8.15M approx. pre-tax spread)
Exercise and Sale
12 txns
Insider
Savitz Ryan
Role
EVP, CFO & CBO
Sold
114,367 shs ($9.49M)
Approx. gross sale proceeds
$9.49M
Approx. exercise cost
$1.34M
Approx. pre-tax spread
$8.15M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 74,367 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 40,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 74,367 | $8.44 | $628K |
| Exercise | Common Stock | 40,000 | $17.88 | $715K |
| Sale | Common Stock | 1,390 | $78.33 | $109K |
| Sale | Common Stock | 21,825 | $78.86 | $1.72M |
| Sale | Common Stock | 1,485 | $80.25 | $119K |
| Sale | Common Stock | 800 | $81.36 | $65K |
| Sale | Common Stock | 2,366 | $82.84 | $196K |
| Sale | Common Stock | 59,800 | $83.90 | $5.02M |
| Sale | Common Stock | 19,469 | $84.57 | $1.65M |
| Sale | Common Stock | 7,232 | $85.54 | $619K |
Holdings After Transaction:
Stock Option (Right to Buy) — 90,399 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (11)
- F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025.
- F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $77.74 to $78.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $78.74 to $79.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.11 to $81.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.15 to $81.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F6. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.25 to $83.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F7. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.25 to $84.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F8. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.25 to $85.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F9. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.25 to $85.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F10. The shares of common stock underlying this stock option award vested as to 25% of the shares on June 2, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
- F11. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Options exercised: 114,367 shares
Option strike price 1: $8.44 per share
Option strike price 2: $17.88 per share
+4 more
7 metrics
Options exercised
114,367 shares
Total common shares acquired via option exercises on March 31, 2026
Option strike price 1
$8.44 per share
Exercise price for 74,367 stock option shares
Option strike price 2
$17.88 per share
Exercise price for 40,000 stock option shares
Shares sold
114,367 shares
Total Dianthus common shares sold in open-market transactions
Sale price range (weighted averages)
$78.33–$85.54 per share
Weighted average prices for disclosed sale blocks
Post-transaction common stock
0 shares
Direct common stock holdings after final reported sale
10b5-1 plan adoption date
December 30, 2025
Date Ryan Savitz adopted the Rule 10b5-1 trading plan
Key Terms
Rule 10b5-1 trading plan, weighted average price, stock option (right to buy), open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging..."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock option (right to buy) financial
"Stock Option (Right to Buy) ... Exercise or conversion of derivative security"
open-market sale financial
"transaction_action: open-market sale ... Sale in open market or private transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Dianthus Therapeutics (DNTH) EVP, CFO & CBO Ryan Savitz do in this Form 4?
Ryan Savitz exercised stock options and then sold the resulting shares. He acquired 114,367 Dianthus Therapeutics common shares through option exercises and sold the same 114,367 shares in multiple open-market transactions disclosed in this Form 4.
What stock options did Ryan Savitz exercise in the Dianthus Therapeutics (DNTH) filing?
He exercised two stock option awards covering a total of 114,367 shares of Dianthus common stock. One option covered 74,367 shares at an exercise price of $8.44 per share, and another covered 40,000 shares at an exercise price of $17.88 per share.
Does Ryan Savitz still hold Dianthus Therapeutics (DNTH) common stock after these transactions?
According to the reported holdings, he does not hold Dianthus common stock directly after these transactions. The final line of the non-derivative transaction table shows total shares of common stock following the last sale as 0.0000, indicating no remaining direct common share ownership.
Were Ryan Savitz’s Dianthus Therapeutics (DNTH) stock sales under a Rule 10b5-1 plan?
Yes. A footnote states the reported sales were effected under a Rule 10b5-1 trading plan adopted by Ryan Savitz on December 30, 2025. Such plans are pre-arranged trading programs that schedule future transactions according to predetermined instructions.
How does this Dianthus Therapeutics (DNTH) Form 4 classify the transactions overall?
The filing shows derivative exercises and open-market sales, resulting in a net disposition. The transaction summary reports 2 derivative exercises totaling 114,367 shares and 8 sale transactions totaling 114,367 shares, producing a net-sell share balance of 114,367.
AI-generated analysis. How Rhea-AI works. Not financial advice.
